Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Irving Sucholeiki
President & CEO

Message the company or request a 1:1 meeting here

Aquilus Pharmaceuticals (Aquilus) is a biotech company focused on the treatment and management of Amyotrophic Lateral Sclerosis (ALS), neuropathic pain, and other neurological disorders. The company has a portfolio of highly potent and proprietary matrix metalloproteinase (MMP) inhibitors. This includes a dual-active matrix metalloproteinase-9 (MMP-9) and MMP-2 inhibitor, designated AQU-118, for the treatment of ALS and neuropathic pain. AQU-118 affects various key inflammatory pathways that reduce nerve injury and cell death (apoptosis). AQU-118 is orally bioavailable and has exhibited excellent safety in mice, rats, and dogs. Aquilus’ primary goal is to pursue clinical development of AQU-118 as a first-in-class treatment for ALS. Aquilus is pre-Series A and funded through grants awards from the ALS Association Lawrence and Isabel Barnett Drug Development Program, the National Institutes of Health (NIH), and the Department of Defense (DOD) ALS Research Program. Aquilus is currently fully funded and is on track to complete all of its remaining Investigational New Drug (IND)-enabling studies for AQU-118 by the end of 2022. Aquilus hopes to file its completed IND for AQU-118 with the FDA by the first quarter of 2023 and begin clinical testing by end of 2023. Aquilus is currently looking for investors to raise a series A round that will fund the clinical testing of AQU-118 in a Phase 1/2 clinical trial for the treatment of ALS

Pitch Video

Slide Deck